Clinical Trials Logo

Toxemia clinical trials

View clinical trials related to Toxemia.

Filter by:

NCT ID: NCT05157360 Terminated - Sepsis Clinical Trials

HAT for the Treatment of Sepsis Associated With NASTI

Start date: September 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.

NCT ID: NCT05148117 Not yet recruiting - Sepsis Clinical Trials

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Start date: December 10, 2024
Phase:
Study type: Observational

This proposal hypothesizes that mitochondrial bioenergetics in the patient will correspond to mtDNA DAMPs levels and markers of inflammation. We predict these will serve as a prognostic indicator of Sepsis induced cardiac dysfunction (SICD) outcomes. Successful completion of these studies will provide a clearer understanding of the etiology of SICD development and therefore will have a high impact on biomedical research by identifying a new mechanism for understanding sepsis induced organ failure. Importantly, they will also provide a means for more directed and focused therapies, based upon individual bioenergetic/mitochondrial-mediated inflammation profiles. The combined, complementary expertise of the Mentor/co-primary investigators (Drs. Mathru and Ballinger) provide an excellent combination in both basic and translational research. They also have experience conducting studies and publications that will strengthen this research project. Importantly, the methods for characterizing mitochondrial bioenergetics from platelets were developed here at UAB, and methods for quantitative assessment of mtDNA DAMPs have been recently developed.

NCT ID: NCT05142813 Not yet recruiting - Sepsis Clinical Trials

A Blood Test to Diagnose Sepsis in Symptomatic Adults and Children

Start date: May 2022
Phase:
Study type: Observational

A case-control cohort study to develop and validate the performance of a whole blood gene expression test to distinguish sepsis infection from uninfected systemic inflammatory response syndrome cases in symptomatic adults and children without comorbidities.

NCT ID: NCT05139459 Completed - Sepsis Clinical Trials

Sepsis Characterization in Kilimanjaro

SICK
Start date: January 17, 2022
Phase:
Study type: Observational

The aim of this study is to prospectively evaluate the barriers to care, evaluation, clinical practices, and outcomes for patients presenting with sepsis to hospitals in the Kilimanjaro Region of northern Tanzania. This will include an assessment of timing and selection of antimicrobials and administration and volume of intravenous fluids. The study also aims to characterize sepsis sub-types in the epidemiologic context of northern Tanzania using statistical clustering techniques of clinical variables and of host immune response patterns.

NCT ID: NCT05136560 Recruiting - Sepsis Clinical Trials

Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis

Start date: January 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of early administration of two different doses of dexamethasone in high risk septic patients.

NCT ID: NCT05133310 Recruiting - Sepsis Clinical Trials

Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia

Start date: November 19, 2021
Phase: Phase 4
Study type: Interventional

In general, the percentage of complete remissions is 85 - 90 % for acute lymphoid leukemia (ALL). In developing countries, percentages are lower secondary to higher sepsis-related mortality. Although the effect of statins on inflammatory response associated with sepsis has been demonstrated, including an effect on bacterial proliferation in patients with a state of immunosuppression, their effect has not been demonstrated so far in patients with hemato-oncological cancer.

NCT ID: NCT05124327 Completed - Preeclampsia Clinical Trials

Remote Monitoring and Follow-up for Postpartum Hypertensive Disorders of Pregnancy

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The literature unequivocally supports follow-up in the postpartum period post hospital discharge in hypertensive patients, compared to uncomplicated delivery follow-up recommendations of 4-6 weeks postpartum, leading to decreased morbidity and mortality, utilizing at-home blood pressure monitoring and virtual/telemedicine appointments. There is much evidence that telemedicine visits are equally, if not more effective, result in cost savings, and are generally preferred by patients, specifically when there is a risk of exposure for the patient and newborn, an appropriate factor to consider amidst the global Covid-19 pandemic. Maternal health and well-being have substantial links with cultural and racial factors. Black women are three times as likely to have morbid outcomes related to gestational complications, specifically hypertensive disorders of pregnancy. Minority populations have historically displayed inferior access to care due to concerns related to transportation, healthcare insurance, or provider accessibility and distrust, resulting in diminished compliance with follow-up and negative health sequelae. Telemedicine follow-up within 10 days of delivery (48-72 hours after discharge) reduces readmission rates, increase access to- and compliance with care, and improve patient safety satisfaction, thus establishing feasibility. Home vital sign monitoring gives an increased volume of data points for providers to utilize in titrating antihypertensive medications to optimize blood pressure control, ultimately decreasing stroke and cardiovascular risk. Existing research lacks comprehension regarding specific cardiological impacts of labile postpartum blood pressures, however researchers inferentially hypothesize that poor blood pressure management in the postpartum period can have devastating long-term cardiological consequences. This QI project will demonstrate standardized programming for patients with hypertensive disorders of pregnancy (HDP), which may potentially lead to increased compliance, satisfaction, and accessibility, resulting in improved long-term cardiovascular health in vulnerable populations. The American heart Association (AHA) and ACOG have established that HDP are associated with long-term cardiovascular disease, however obstetricians lack guidance on effective, evidence-based research for standardization of care, leading to subsequently disjointed medical management with much room for error in transitioning from obstetrician to internist or cardiologist. Thus, implementing and establishing feasibility of remote monitoring and follow-up while applying standardized algorithms and protocols for antihypertensive medication titration and management may provide support in addressing and eradicating these gaps. As such, this pilot project has massive prospective future applicability and benefit for a highly vulnerable population.

NCT ID: NCT05114057 Not yet recruiting - Acute Kidney Injury Clinical Trials

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Taking Focus 2
Start date: September 1, 2024
Phase: N/A
Study type: Interventional

This study will follow patients admitted to the PICU with sepsis, NICU with sepsis or after abdominal surgery, or CICU who are identified as being at risk for developing acute kidney injury. The investigators will use risk-stratification, biomarker testing, and a functional assessment to predict children and neonates who will become fluid overloaded and develop severe acute kidney injury.

NCT ID: NCT05112406 Not yet recruiting - Sepsis Clinical Trials

Early Diagnostic Biomarkers of Sepsis

Start date: December 2021
Phase:
Study type: Observational

A Comparison between CRP, ferritin, and serum zinc as early diagnostic biomarkers of sepsis in critically ill patients

NCT ID: NCT05111769 Not yet recruiting - Sepsis Clinical Trials

Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The investigators intend to conduct clinical studies to determine the efficacy of rhBNP in the treatment of septic related dysfunction and kidney dysfunction